Patent: 10,001,483
✉ Email this page to a colleague
Summary for Patent: 10,001,483
| Title: | Methods for the treatment of Kaposi\'s sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers |
| Abstract: | Provided herein are uses of gene and protein biomarkers as a predictor of clinical sensitivity of Kaposi\'s sarcoma (KS) or Kaposi\'s sarcoma-associated herpesvirus (KSHV) induced lymphoma and patient response to treatment with an immunomodulatory compound. Further provided herein are methods for the treatment or management of Kaposi\'s sarcoma or KSHV-induced lymphoma with an immunomodulatory compound, alone or in combination with doxorubicin. |
| Inventor(s): | Yarchoan; Robert (Bethesda, MD), Zeldis; Jerome B. (Princeton, NJ), Polizzotto; Mark N. (New South Wales, AU), Davis; David A. (Bethesda, MD), Sereti; Irini (Washington, DC), Uldrick; Thomas S. (Washington, DC), Whitby; Denise (Frederick, MD), Khetani; Vikram (Short Hills, NJ) |
| Assignee: | Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) |
| Application Number: | 15/192,819 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,001,483
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | ⤷ Try a Trial | 2035-06-26 |
| Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | Injection | 125514 | 01/15/2015 | ⤷ Try a Trial | 2035-06-26 |
| Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 12/22/2014 | ⤷ Try a Trial | 2035-06-26 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
